Litemed
1 known investors
LiteMed develops Curapod, an adaptive pain management device that delivers personalized relief by penetrating up to 70mm into tissue to target deep-seated pain. It offers precision dosage across a wide pain area with results reported within a 30-minute session.
Also known as Curapod · Litemed India Private Limited
Founders & leadership
Investors · 1
Company profile
researched Aug 2026Litemed is an India-based medical device company whose product is Curapod, a compact, wearable, rechargeable light therapy device for joint, muscle and chronic pain management. Curapod applies photobiomodulation (also referred to as low-level laser or light therapy) using red and near-infrared wavelengths that target cellular mitochondria, with the stated aim of reducing inflammation, improving local circulation and supporting tissue repair. The device is positioned as non-invasive and drug-free, used in 30-minute sessions and paired with a companion Curapod app.
The company describes Curapod as an adaptive pain management system using dual-wavelength light with deeper penetration for personalized therapy. Marketed applications span joint and muscle pain (knee, shoulder, hip, neck, back, arthritis, muscle soreness and strains), chronic and nerve-related discomfort (sciatica, tendinitis, bursitis, carpal-tunnel-related discomfort, cervical and lumbar pain) and conditions such as plantar fasciitis and frozen shoulder. The company states Curapod is a CDSCO-approved Class B medical device sold with a one-year warranty.
The retail box contains two Curapod devices, a power adaptor, two Type-C charging cables, dongles, 50 adhesive patches, two adjustable straps, two casings, a quick start guide and a user manual. Litemed also notes an updated exterior casing finish on current units, with unchanged wavelengths, output, session length, app and accessories.
Founding story
Litemed was founded around the premise that red and near-infrared light therapy could address underlying causes of chronic pain rather than provide only temporary relief. Co-founders are Sriram Velliyur (Founder/CEO), described as having over 25 years of experience in the technology industry, and Dr. Surya Prakash (Dr. Suryaprakash Maguluri, Founder/CTO), described as an expert in light-based research with over five years of experience.
Business model
Direct-to-consumer sale of a hardware medical device through the company's own online store, supported by accessory consumables (adhesive patches, straps), a companion app, customer support via email and WhatsApp, and free expert consultation lead capture.
Product sales of the Curapod device, listed at Rs. 8,399 (tax included), with promotional discount codes, zero-cost EMI options and free shipping on prepaid orders; accessories such as adhesive patches are bundled or offered as promotions.
Traction
The company states Curapod is used daily by more than 25,000 users and displays 582 verified product reviews on its site plus a customer review page based on 628 reviews, of which 73% are five-star and 26% four-star.
Latest developments
Curapod is shipping with an updated exterior casing finish while retaining the same wavelengths, output, 30-minute session protocol, app, accessories and one-year warranty. The company notes an app usability upgrade is in progress in response to customer feedback.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positions Curapod as the world's first adaptive pain management device; backed by Ideaspring Capital, which lists Litemed under its Fund II BioTech / life sciences portfolio.
Marketed as the world's first adaptive pain management device delivering personalized dosage with dual-wavelength, deeper-penetrating light; non-invasive and drug-free; CDSCO-approved Class B medical device; supported by a randomized, double-blind, placebo-controlled multicentric clinical study.
Technology
Photobiomodulation using red and near-infrared light at dual wavelengths delivered through a portable, hands-free, rechargeable device. The company states the light penetrates up to deeper tissue levels to act at molecular and tissue levels, with 30-minute therapy sessions managed via an accompanying app. Marketed features include precision dosage over a wide pain area and an ergonomic, lightweight, travel-friendly form factor.
Go-to-market
Online direct sales via the company's e-commerce site with discount campaigns and EMI financing, supported by testimonial-driven marketing from physicians, physiotherapists and professional athletes, free expert consultations, and clinical evidence positioning.
Individuals with acute and chronic musculoskeletal pain, including arthritis, lower back pain, fibromyalgia, plantar fasciitis, cervical spondylitis and post-operative pain; also used by clinicians (spine and orthopedic surgeons, physiotherapists) and athletes for recovery and injury management.
Geography
Operations centred in India; pricing is in Indian rupees, an Indian support phone line is provided, and clinical trial sites are in Chennai and Hyderabad.
History
Litemed developed Curapod through a stated validation pathway of prototype development, electronic and safety certifications, clinical evaluation and regulatory approvals, culminating in CDSCO Class B medical device approval and direct-to-consumer sales in India. It is a portfolio company of Ideaspring Capital's Fund II.
Risks & controversies
Marketing relies heavily on customer and practitioner testimonials and self-reported efficacy claims (for example, relief within 30 minutes and percentage pain reductions); the clinical study is described on the company's own site without published results. Customer feedback has cited limitations in the companion app's usability.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsVenture firm Ideaspring Capital lists Litemed in its portfolio under Fund II, in the BioTech / life sciences category; no amount or date is stated.
Curapod units now ship with a redesigned outer casing while retaining the same wavelengths, output, 30-minute sessions, app, accessories and one-year warranty.
Litemed states that Curapod is approved by India's CDSCO as a Class B medical device, sold with a one-year warranty.
The company describes a randomized, double-blind, placebo-controlled multicentric study evaluating the safety and performance of Curapod, conducted at Apollo Hospitals (Chennai), Sri Ramachandra Hospital (Chennai), KIMS Hospital Enterprises (Hyderabad) and Nizam's Institute of Medical Sciences (Hyderabad).
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Litemedlitemed.co.in · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Litemed do?
- Indian medtech company selling Curapod, a wearable red and near-infrared light therapy device for pain management.
- Who founded Litemed?
- Litemed was founded by Sri Velliyur.
- Who are Litemed's investors?
- Litemed's investors include V3 Ventures.